Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

por Zhang, Qunling, Cao, Junning, Xue, Kai, Liu, Xiaojian, Ji, Dongmei, Guo, Ye, Hong, Xiaonan
Publicado 2016

A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma

por Luo, Zhiguo, Zhang, Xiaowei, Peng, Wei, Wu, Xianghua, Wang, Huijie, Yu, Hui, Wang, Jialei, Chang, Jianhua, Hong, Xiaonan
Publicado 2015

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

por Liu, Yizhen, Liu, Yumei, Zhao, Ping, Zhang, Qunling, Liu, Xiaojian, Lv, Fangfang, Hong, Xiaonan, Cao, Junning, Xue, Kai
Publicado 2020

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

por Hong, Xiaonan, Song, Yuqin, Huang, Huiqiang, Bai, Bing, Zhang, Huilai, Ke, Xiaoyan, Shi, Yuankai, Zhu, Jun, Lu, Guodong, Liebscher, Stefan, Cai, Chunxiao
Publicado 2019

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study

por Hong, Xiaonan, Song, Yuqin, Shi, Yuankai, Zhang, Qingyuan, Guo, Wei, Wu, Gang, Li, Junmin, Feng, Jifeng, Kinkolykh, Anastasiia, Knapp, Andrea, Lin, Tongyu
Publicado 2022

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

por Jin, Jia, Ji, Dongmei, Xia, Zuguang, Xue, Kai, Zhang, Qunling, Liu, Yizhen, Cao, Junning, Hong, Xiaonan, Gu, Juan J., Guo, Ye, Lv, Fangfang
Publicado 2022

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study

por Ji, Dongmei, Li, Qiu, Cao, Junning, Guo, Ye, Lv, Fangfang, Liu, Xiaojian, Wang, Biyun, Wang, Leiping, Luo, Zhiguo, Chang, Jianhua, Wu, Xianghua, Hong, Xiaonan
Publicado 2016

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

por Jin, Jie, Okamoto, Rumiko, Yoon, Sung-Soo, Shih, Lee-Yung, Zhu, Jun, Liu, Ting, Hong, Xiaonan, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Huang, Huiqiang
Publicado 2018

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T‐cell lymphoma patients

por Liu, Yizhen, Xue, Kai, Xia, Zuguang, Jin, Jia, Wang, Jiachen, Sun, Hui, Lv, Fangfang, Liu, Xiaojian, Cao, Junning, Hong, Xiaonan, Guo, Ye, Ma, Xuejun, Zhang, Qunling
Publicado 2020

Prognostic significance of clinical characteristics and (18)Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary med...

por Liu, Yizhen, Jiang, Jinjin, Liu, Lianfang, Wang, Zezhou, Yu, Baohua, Xia, Zuguang, Zhang, Qunling, Ji, Dongmei, Liu, Xiaojian, Lv, Fangfang, Hong, Xiaonan, Song, Shaoli, Cao, Junning
Publicado 2022

Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK...

por Zhang, Yao, Liu, Yizhen, Xia, Zuguang, Jin, Jia, Xue, Kai, Wang, Jiachen, Sun, Hui, Lv, Fangfang, Liu, Xiaojian, Cao, Junning, Hong, Xiaonan, Guo, Ye, Ma, Xuejun, Zhang, Qunling
Publicado 2021

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial

por Xue, Kai, Gu, Juan J., Zhang, Qunling, Liu, Xiaojian, Wang, Jiachen, Li, Xiao-qiu, Luo, Jianfeng, Hernandez, Francisco J., Fernandez, Stanley F., Czuczman, Myron S., Cao, Junning, Hong, Xiaonan, Guo, Ye
Publicado 2016

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positiv...

por Shi, Yuankai, Zhang, Qingyuan, Han, Xiaohong, Qin, Yan, Ke, Xiaoyan, Su, Hang, Liu, Li, Fu, Jinxiang, Jin, Jie, Feng, Jifeng, Hong, Xiaonan, Zhang, Xiaohong, Wu, Depei, Jiang, Bin, Dong, Xiaodong
Publicado 2021

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance

por Liu, Yizhen, Gu, Juan J., Yang, Ling, Tsai, Ping-Chiao, Guo, Ye, Xue, Kai, Xia, Zuguang, Liu, Xiaojian, Lv, Fangfang, Cao, Junning, Hong, Xiaonan, Mavis, Cory, Hernandez-Ilizaliturri, Francisco J., Zhang, Qunling
Publicado 2020

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma

por Chen, Guang-Liang, Li, Doudou, Cao, Sufen, Jiang, Shiyu, Zhang, Qunling, Jin, Jia, Xia, Zuguang, Liu, Yizhen, Liu, Xiaojian, Zhu, Yanzhe, Chen, Yu, Gu, Lingli, Hong, Xiaonan, Cao, Junning, Tao, Rong, Lv, Fangfang
Publicado 2022

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

por Liu, Xin, Guo, Weijian, Zhang, Wen, Yin, Jiliang, Zhang, Jun, Zhu, Xiaodong, Liu, Tianshu, Chen, Zhiyu, Wang, Biyun, Chang, Jianhua, Lv, Fangfang, Hong, Xiaonan, Wang, Huijie, Wang, Jialei, Zhao, Xinmin, Wu, Xianghua, Li, Jin
Publicado 2017

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell ly...

por Zhu, Jun, Hong, Xiaonan, Song, Yu Qin, Hodkinson, Brendan, Balasubramanian, Sriram, Wang, Songbai, Zhang, Qingyuan, Shi, Yuankai, Huang, Huiqiang, Zhang, Huilai, Zhu, Yan, Shreeve, Stephen Martin, Sun, Steven, Wang, Ze, Wang, Xiaocan, Fan, Yue, Wilson, Wyndham, Vermeulen, Jessica
Publicado 2022

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study

por Kostakoglu, Lale, Mattiello, Federico, Martelli, Maurizio, Sehn, Laurie H., Belada, David, Ghiggi, Chiara, Chua, Neil, González-Barca, Eva, Hong, Xiaonan, Pinto, Antonio, Shi, Yuankai, Tatsumi, Yoichi, Bolen, Christopher, Knapp, Andrea, Sellam, Gila, Nielsen, Tina, Sahin, Deniz, Vitolo, Umberto, Trněný, Marek
Publicado 2021

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

por Leonard, John P., Trneny, Marek, Izutsu, Koji, Fowler, Nathan H., Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W., Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G.
Publicado 2019

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

por Nowakowski, Grzegorz S., Chiappella, Annalisa, Gascoyne, Randy D., Scott, David W., Zhang, Qingyuan, Jurczak, Wojciech, Özcan, Muhit, Hong, Xiaonan, Zhu, Jun, Jin, Jie, Belada, David, Bergua, Juan Miguel, Piazza, Francesco, Mócikova, Heidi, Molinari, Anna Lia, Yoon, Dok Hyun, Cavallo, Federica, Tani, Monica, Yamamoto, Kazuhito, Izutsu, Koji, Kato, Koji, Czuczman, Myron, Hersey, Sarah, Kilcoyne, Adrian, Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan, Wade, Steve, Witzig, Thomas E., Vitolo, Umberto
Publicado 2021